Ongoing studies have explored the monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) treatment for AML by targeting CTLA4 or PD1/PD-L1 pathway (67). The gene discussed is CD274; the disease is acute myeloid leukemia.